124842-29-1

Basic information

• Product Name: Carbamic acid, [(3S)-2,5-dioxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester
• CAS NO: 124842-29-1
• Molecular Formula: C9H14N2O4
• Molecular Weight: 214.221
• Mol File: 124842-29-1.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [(3S)-2,5-dioxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(3S)-2,5-dioxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester(124842-29-1)
• EPA Substance Registry System: Carbamic acid, [(3S)-2,5-dioxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester(124842-29-1)

Safety Data

• Hazardous Substances Data: 124842-29-1(Hazardous Substances Data)

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 7536-55-2 N-tert-butyloxycarbonylasparagine 
• 7536-55-2 N-t-butyloxycarbonyl-D-asparagine 

Downstream Products

• 706780-18-9 N-benzyl-3-Boc-aminopyrrolidin-2,5-dione 

Relevant articles and documents

De-novo design of cereblon (CRBN) effectors guided by natural hydrolysis products of thalidomide derivatives

Targeted protein degradation via cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase complex, is an increasingly important strategy in various clinical settings, in which the substrate specificity of CRBN is altered via the binding of small-molecule effectors. To date, such effectors are derived from thalidomide and confer a broad substrate spectrum that is far from being fully characterized. Here, we employed a rational and modular approach to design novel and minimalistic CRBN effectors. In this approach, we took advantage of the binding modes of hydrolyzed metabolites of several thalidomide-derived effectors, which we elucidated via crystallography. These yielded key insights for the optimization of the minimal core binding moiety and its linkage to a chemical moiety that imparts substrate specificity. Based on this scaffold, we present a first active de-novo CRBN effector that is able to degrade the neo-substrate IKZF3 in the cell culture.

DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS

Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.

SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION

Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.